Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Shawn Dhillon (NPI 1215914437)

Key Findings

Field	Value
Entity Type	Individual
Organization	Shawn Dhillon
Address	2 Hamill Rd Ste 272
City	Baltimore
State	MD
ZIP	21210
Taxonomy	Internal Medicine Physician
NPI Enumerated	December 29, 2005

Payer Source	Total Paid
Medicare	$3.1M
Medicaid	$0

Medicare revenue is highly concentrated: total Medicare revenue is $3.1M and the precomputed top 3 Medicare codes by revenue account for 97.7% of this provider's total Medicare revenue, with J2507 alone representing $2.9M (94.6% of the provider's Medicare revenue). This concentration means a single high-cost code drives the vast majority of reported Medicare dollars.

The provider’s code mix and top revenue driver indicate a specialty infusion/service-line focus: J2507 (pegloticase injection) dominates revenue, which aligns with operation of an infusion or biopharmaceutical administration service. Supporting activity in infusion- and chemotherapy-related codes (96413, 96415, 96374, 96375) and monitoring codes suggests on-site medication administration capacity beyond routine office visits.

This profile is effectively single-payer on file: the provider reports $3.1M in Medicare revenue and has no Medicaid billing on file (none below). Analysts should treat this entity as Medicare-centric for network, utilization, and contracting considerations rather than as a mixed Medicaid/Medicare practice.

Competitive standing for the primary drug code is notable but occurs within a tiny national peer group: the provider ranks #2 of 5 nationally for J2507 (75th percentile; typical, unremarkable volume for this code). Being second among only five billing providers indicates the practice is one of a small set of Medicare billers for pegloticase, so market position depends on a narrow, specialized cohort rather than broad outpatient volume.

Routine evaluation-and-management activity is unusually high in count but low in revenue share: 99213 appears 1.1K times for $60.2K revenue (1.9% of Medicare revenue) and 99214 appears 457 times for $36.1K revenue (1.2%); 99213 ranks #5157 of 457151 providers nationally (99th percentile; extreme outlier, far above typical national volume). This combination — many E/M encounters that collectively contribute little to total revenue — suggests frequent patient follow-up or monitoring visits tied to high-cost infusion therapy rather than a typical primary-care revenue mix.

Several secondary codes show above-typical volumes despite small revenue impact: 96160 (410 claims, $820 revenue) ranks #77 of 1737 providers nationally (96th percentile; notably above typical national volume), 93922 (227 claims, $14.5K revenue) ranks #403 of 8082 (95th percentile; typical, unremarkable volume), and 99406 (89 claims, $1.4K revenue) ranks in the 95th percentile. These elevated percentiles point to consistent use of standardized questionnaires, vascular studies, and tobacco cessation counseling as part of the practice workflow, but none approach the revenue contribution of J2507.

Provider tenure is long-standing: the NPI was enumerated on 2005-12-29 (~21 years ago), indicating an established billing history. That longevity combined with the current, highly concentrated Medicare revenue mix suggests an evolution toward a specialized infusion/biologic service-line over time rather than a newly formed specialty practice.

Operational and payer-management implications flow from extreme revenue concentration: with $2.9M attributable to J2507 and top three codes making up 97.7% of Medicare revenue, any changes in coverage policy, prior authorization, or supply of pegloticase could materially affect topline Medicare payments. Analysts evaluating contracting, utilization management, or audit risk should prioritize specialty drug administration workflows, documentation for high-cost injections, and reconciliation of the high-volume E/M encounters that accompany this therapy.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

27 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2507	Injection, pegloticase, 1 mg	1,150	$2,550	$2.9M
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	1,090	$60	$60.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	460	$80	$36.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	140	$110	$16.1K
93922	Noninvasive physiologic studies of upper or lower extremity arteries, single level, bilateral	230	$60	$14.5K
96415	In this add on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report each additional hour of infusion beyond the…	290	$20	$6.9K
99495	The provider manages the care of a patient during the transition to home care after discharge from a healthcare facility. The patient’s care requires at least moderate medical decision making,…	30	$170	$4.4K
99204	The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider…	30	$130	$3.9K
93306	The provider uses transducers to obtain two–dimensional (2D) images of the heart structures through the chest wall. He evaluates the anatomy and function of all four heart chambers, valves, adjacent…	20	$160	$3.5K
96374	The provider administers a single medication or other substance rapidly into a vein to treat, prevent, or diagnose a condition.	110	$30	$3.4K

Showing 1–10 of 27

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2507	1	10	1,150	$2,540	$2.9M
93306	462	500	290	$110	$38K
96413	137	230	200	$110	$29.6K
99214	1,951	10,270	150	$90	$24.1K
93925	185	230	40	$150	$18.8K
99457	188	210	170	$40	$13.2K
99213	187	9,280	100	$60	$12.5K
99454	209	230	150	$40	$11.7K
77080	281	330	150	$40	$9.1K
95923	27	40	30	$110	$8.5K

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Oluwaseun Ajifowobaje	NY	Physical Therapist	$170.2K	$0
Brian Seymore	MD	Clinical Electrophysiology Physical Therapist	$120.4K	$0
Caren Dinshah	MD	Clinical Electrophysiology Physical Therapist	$85.5K	$0

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dankner Eye Associates P A	MD	Ophthalmology Physician	$0	$4.3M
Brett Levinson	MD	Ophthalmology Physician	$361.9K	$0
John Charlton	MD	Podiatrist	$68.1K	$0
David Lisle	MD	Colon & Rectal Surgery Physician	$66.8K	$0

Shawn Dhillon — Billing Profile & Reimbursement Data

Sign up for Shawn Dhillon — Billing Profile & Reimbursement Data policy alerts

Shawn Dhillon — Billing Profile & Reimbursement Data

Sign up for Shawn Dhillon — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References